GLP‑1 Receptor Agonists and Limb Outcomes: What a 645,000‑Patient Study Tells Us A nationwide retrospective cohort analysis published this week in Diabetes Care explores whether glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs) confer advantages over sodium–glucose cotransporter‑2 inhibitors (SGLT2i) for lower‑extremity events in type 2 diabetes. Led by Dr Tze‑Woei Tan, the investigation examined 645,121 individuals newly started on either drug class between... Continue Reading →